睿知中国医院研究地图
候选清单

即将招募胰腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06888648,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology);

    入选标准第 13 条

  3. Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause;

    入选标准第 9 条

    Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause;

    入选标准第 17 条

  4. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;

    入选标准第 5 条

    An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;

    入选标准第 15 条

  5. According to the efficacy evaluation criteria for solid tumors (RECIST 1.1);

    入选标准第 6 条

  6. At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except;

    排除标准第 2 条

    Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B;

    排除标准第 6 条

  7. Women born during pregnancy or lactation;

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06888648,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary signing of the informed consent form;
  2. Age: 18 and 75 years old, male or female;
  3. Evaluation as metastatic pancreatic cancer or postoperative recurrence according to the 2024 NCCN guidelines;
  4. No systemic treatment, or disease progression with gemcitabine-based first-line chemotherapy.
  5. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
  6. According to the efficacy evaluation criteria for solid tumors (RECIST 1.1);
  7. Can obtain sufficient fresh tumor tissue samples for exome and transcriptome sequencing analysis;
  8. Main organ function of heart, liver and kidney is normal:
  9. Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause;
  10. Ability to follow the study protocol and follow-up procedures.
  11. Voluntary signing of the informed consent form;
  12. Age: 18 and 75 years old, male or female;
  13. Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology);
  14. No systemic treatment or gemcitabine-based first-line chemotherapy.
  15. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
  16. Main organ function of heart, liver and kidney is normal:
  17. Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause;
  18. Ability to follow the study protocol and follow-up procedures.

排除标准:Exclusion Criteria:

  1. Pancreatic cancer has central nervous system metastasis or meningeal metastasis;
  2. At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except;
  3. History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation;
  4. Patients with immunosuppressants, that is, those who require regular use of immunosuppressants 4 weeks before the screening period and the clinical study, including but not limited to the following conditions: severe asthma, autoimmune diseases or immune deficiency, treated with immunosuppressive drugs, and known history of primary immunodeficiency; except type 1 diabetes, autoimmune-related hypothyroidism requiring hormone therapy, vitiligo and psoriasis that do not require systemic therapy;
  5. Active bacterial or fungal infection identified by clinical diagnosis; a history of active TB or tuberculosis;
  6. Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B;
  7. Herpesvirus infection (except those who scab for more than 4 weeks); respiratory virus infection (except those who have recovered for more than 4 weeks);
  8. Uncontrolled complications include but are not limited to active infection, symptomatic congestive heart failure, unstable angina, arrhythmia; severe coronary artery disease or cerebrovascular disease, or other diseases considered unacceptable by the investigator;
  9. Previous history of drug abuse, clinical or psychological or social factors affecting informed consent or study implementation; a history of mental illness;
  10. Patients with a history of food, drug or vaccine allergy or other potential immunotherapy allergies as considered by the Investigator.
  11. Women born during pregnancy or lactation;
  12. The investigator is not fit for enrollment or may not complete the trial for other reasons.

引自 ClinicalTrials.gov, NCT06888648, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06888648,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06888648